Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more
Poolbeg Pharma PLC (POLBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.206x
Based on the latest financial reports, Poolbeg Pharma PLC (POLBF) has a cash flow conversion efficiency ratio of -0.206x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($11.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Poolbeg Pharma PLC - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Poolbeg Pharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Poolbeg Pharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poolbeg Pharma PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Commercial Vehicle Group Inc
NASDAQ:CVGI
|
-0.012x |
|
Crystal Valley Financial Corp
PINK:CYVF
|
N/A |
|
Software Aktiengesellschaft
PINK:SWDAF
|
-0.008x |
|
AMICA S.A. ZY 2
F:9R1
|
N/A |
|
Seoul Auction Co. Ltd
KQ:063170
|
0.048x |
|
Bubs Australia Limited
PINK:BUBSF
|
0.155x |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
0.072x |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Poolbeg Pharma PLC (2021–2024)
The table below shows the annual cash flow conversion efficiency of Poolbeg Pharma PLC from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.27 Million | $-4.65 Million | -0.501x | -65.16% |
| 2023-12-31 | $14.44 Million | $-4.38 Million | -0.303x | -27.25% |
| 2022-12-31 | $18.32 Million | $-4.37 Million | -0.238x | -150.83% |
| 2021-12-31 | $22.58 Million | $-2.15 Million | -0.095x | -- |